Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C1529
http://purl.obolibrary.org/obo/NCIT_C1529
|
|---|---|
| Preferred Name | Batimastat |
| Definitions |
A synthetic hydroxamate with potential antineoplastic activity. Batimastat binds covalently to the zinc ion in the active site of matrix metalloproteinases (MMPs), thereby inhibiting the action of MMPs, inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis. (NCI04)
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A synthetic hydroxamate with potential antineoplastic activity. Batimastat binds covalently to the zinc ion in the active site of matrix metalloproteinases (MMPs), thereby inhibiting the action of MMPs, inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis. (NCI04) |
|---|---|
| prefLabel | Batimastat
|
| label | Batimastat
|
| code | C1529
|
| prefixIRI | NCIT:C1529
|
| in_subset | |
| Preferred_Name | Batimastat
|
| FDA_UNII_Code | BK349F52C9
|
| Contributing_Source | FDA
|
| Chemical_Formula | C23H31N3O4S2
|
| Maps_To | Batimastat
|
| CAS_Registry | 130370-60-4
|
| Legacy Concept Name | Batimastat
|
| type | |
| ALT_DEFINITION | An anticancer drug that belongs to the family of drugs called angiogenesis inhibitors. Batimastat is a matrix metalloproteinase inhibitor.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| Semantic_Type |
Organic Chemical
Pharmacologic Substance
|
| UMLS_CUI | C0215791
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |